The president is appointed by the board and is responsible for the Company’s day-to-day management in accordance with the board’s guidelines and instructions.
The president is responsible for keeping the board informed about the Company’s performance and reporting significant deviations from established business plans and about events with a major impact on the Company’s performance and operations, and for providing the board with relevant decision support in regard to, for example, establishments, investments and other strategic issues. Company management, headed by the Company’s president Jonas Jarvius, consists of people in charge of Q-linea’s key business areas.
Holdings as of February 29, 2020
Chief Executive Officer since 2008
Jonas Jarvius has extensive R&D experience in the field of molecular medicine and molecular biological detection. He has co-founded several companies and is one of the founders of Q-linea. For many years, he has also held senior positions in various biotech companies and in these roles, has successfully managed projects related to molecular detection for safety applications and the manufacture and development of medical devices. He also has experience in ISO 13485 certification, a quality management standard for medical devices. In addition, he has been involved in several biotech start-ups that have evolved into large organisations.
Education: PhD in molecular medicine, Uppsala University (2006); MSc in medical science, Uppsala University (1999).
Other ongoing assignments: Jonas Jarvius is chairman of of the board of Umbrella Science AB and a member of the board of directors of QuiaPEG Pharmaceuticals Holding AB (publ).
Holdings in the Company: Jonas Jarvius owns 362,152 shares and 32 250 performance share rights in the Company. He owns an additional 14,705 shares in the Company through his wholly owned company Umbrella Science AB.
Vice President, Research Director
Employed by the Company since 2013, vice president since 2016 and research director since 2017
Mats Gullberg has extensive experience in product development and commercialisation and works with intellectual property issues in biotech companies. He has previously worked with methods of microbiology and molecular biology at Uppsala University. He has vast experience in R&D projects and in running projects to identify potential future products. Over the past ten years, he has been responsible for patent and intellectual property issues, previously at the Olink AB biotech company and since 2013 at Q-linea. Since 2017, he is also responsible for the Company’s research department.
Education: PhD in medical sciences, Uppsala University (2003); MSc in pharmaceutical bioscience (microbiology), Uppsala University (1995).
Other ongoing assignments: Mats Gullberg is a director at EMPE Diagnostics AB.
Holdings in the Company: Mats Gullberg owns 9,601 shares and 12 620 performance share rights and holds 350 employee share options in the Company. These options carry entitlement to acquire 7,000 shares in the Company.
Chief Commercial Officer since 2019
Thomas Fritz has more than 20 years of broad commercial experience in Microbiology, working in Clinical, Pharmaceutical and Industrial end markets. He was leading Marketing, Sales and Customer Service & Support organisations in various regions and was also Managing Director for a large manufacturing site.
In his previous role he served as Senior Director Commercial EMEA for the Microbiology Division of Thermo Fisher Scientific.
Education: Msc in Microbiology, Tuebingen University, Germany (1993)
Other ongoing assignments: Thomas Fritz is Co-Owner and Managing Director of ATC GmbH
Holdings in the Company: –
Chief Financial Officer and Investor Relations since 2018
Anders Lundin has more than 20 years’ experience in financial work and leadership in international organisations operating in the medical technology and pharmaceutical industries. He has previously served as the CFO of a company listed on Nasdaq Stockholm and was also responsible for a listing on the Nasdaq Stock Market in the US and the associated raising of new equity capital.
Education: MSc in economics, Uppsala University (1992).
Other ongoing assignments: Anders Lundin is a founder and member of the board of directors of CFO Akuten AB.
Holdings in the Company: Anders Lundin owns 12 620 performance share rights in the Company. Through his wholly owned company CFO Akuten AB he holds 14,705 shares in the Company.
Chief Operating Officer
Employed by the Company since 2014, Chief Operating Officer since 2017
Nils Kristensen has extensive experience in R&D and the commercialisation of products in the life sciences and telecom industries. He has extensive experience in leadership and project management and has more than 30 years of experience in leading operations and running research and development projects. His main focus area has been manufacturing projects and in these he has worked with optimization, lean management and quality management systems.
Education: MSc in engineering physics, Uppsala University (1998); licentiate of engineering in materials science, Uppsala University (1991).
Other ongoing assignments: Nils Kristensen is a member of the board of directors and the CEO of Kristensen Consulting AB.
Holdings in the Company: Nils Kristensen owns 441 shares and 12 620 performance share rights and holds 505 employee share options in the Company. These options carry entitlement to acquire 10,100 shares in the Company.
Sales and Marketing Director
Employed by the Company since 2016, Marketing Director since 2017, Sales and Marketing Director since 2020
Charlotta Göransson is a former researcher and has worked in sales and marketing in the biotech industry since 2003. She has experience in international sales as well as project management.
Education: PhD in molecular medicine, Uppsala University (2001); MSc in molecular biology, Uppsala University (1995).
Other ongoing assignments: Charlotta Göransson has no other current assignments.
Holdings in the Company: Charlotta Göransson owns 441 shares and 12 620 performance share rights and holds 350 employee share options in the Company. These options carry entitlement to acquire 7,000 shares in the Company.
Tiziana Di Martino
Chief Medical Officer
Chief Medical Officer since 2019
Tiziana Di Martino has more than 16 years’ experience in clinical practice, research and medical/clinical affairs positions in the microbial diagnostic industry. She has previously served as Regional Medical Affairs Manager at Abbott Molecular, Clinical and Scientific Affairs Manager EMEA at Abbott Point of Care and Head of Clinical Development EMEA at Accelerate Diagnostics. In these roles she has successfully managed clinical projects related to new product launches.
Education: MD degree, Università Cattolica del Sacro Cuore in Rome (2003); MSc in Toxicology, University of Surrey (2011), MBA degree, London Business School (2014).
Other ongoing assignments: Tiziana Di Martino has no other current assignments.
Holdings in the Company: –
Director Product Development
Director Product Development since 2017
Jonas Melin has extensive R&D experience and a deep understanding of technical and regulatory issues. He has experience in project management and has successfully led projects from development to regulatory approval. His previous positions include project manager for Meritas D-Dimer test, Troponin test and BNP test and head of technical development of Meritas troponin I.
Education: PhD in engineering science, Uppsala University (2006); MSc in technical biology, Linköping University (2002).
Other ongoing assignments: Jonas Melin is a member of the board of directors of Melin Science AB.
Holdings in the Company: Jonas Melin owns 441 shares and 12 620 performance share rights in the Company.
Director Contract Development
Director Contract Development since 2018
Karl Sköld has a background as a researcher in molecular biology and pharmaceutical life sciences at Uppsala University. In the years 2007 to 2016 he was active as founder, board member and research director of Denator AB, a company that has developed and sells systems for heat stabilisation of clinical samples. Furthermore, he is co-founder of Maurten AB, which develops energy and nutritional products to athletes and the healthcare industry. In 2017, he became CEO of Umbrella Science AB whose operations were acquired by Q-linea in the summer of 2018.
Education: PhD in pharmaceutical bioscience, Uppsala University, 2006.
Other ongoing assignments: Karl Sköld is a mber of the board of directors of Hardcover AB and a deputy boardmember of Laminaria Group AB and Maurten AB.
Holdings in the Company: Karl Sköld owns 12 620 performance share rights in the Company. Through his wholly owned company Hardcover AB he holds 1,029 shares in the Company.